Charles R. Drew University of Medicine and Science
Chez M, Sila CA, Ransohoff RM, Longworth DL, Weida C
Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes. Neurology. 1989 Dec; 39(12):1578-80.
Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes.
Altered metabolic incorporation of fucose and leucine into PNS myelin of 25-week-old diabetic (C57BL/Ks [db/db]) mice: effects of untreated diabetes on nerve metabolism. Neurochem Res. 1983 Apr; 8(4):465-72.
Altered metabolic incorporation of fucose and leucine into PNS myelin of 25-week-old diabetic (C57BL/Ks [db/db]) mice: effects of untreated diabetes on nerve metabolism.
Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK
Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999 May; 134(5):607-13.
Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders.
Chez MG, Hammer MS, Loeffel M, Nowinski C, Bagan BT
Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J Child Neurol. 1999 Apr; 14(4):239-42.
Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid.
Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004 Mar; 19(3):165-9.
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
Chez MG, Buchanan T, Aimonovitch M, Mrazek S, Krasne V, Langburt W, Memon S
Frequency of EEG abnormalities in age-matched siblings of autistic children with abnormal sleep EEG patterns. Epilepsy Behav. 2004 Apr; 5(2):159-62.
Frequency of EEG abnormalities in age-matched siblings of autistic children with abnormal sleep EEG patterns.
Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, Kwon JM, Riviello JJ, Robinson RG, Neuman RJ, Deuel RM
Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry. 2006 Feb 15; 59(4):354-63.
Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy.
Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M
Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007 Jun; 36(6):361-5.
Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children.
Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C
Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007 May; 22(5):574-9.
Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.
Parker KJ, Garner JP, Oztan O, Tarara ER, Li J, Sclafani V, Del Rosso LA, Chun K, Berquist SW, Chez MG, Partap S, Hardan AY, Sherr EH, Capitanio JP
Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates. Sci Transl Med. 2018 05 02; 10(439).
Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates.
Chez M, Kile S, Lepage C, Parise C, Benabides B, Hankins A
Journal of autism and developmental disorders
A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism. J Autism Dev Disord. 2020 May; 50(5):1532-1538.
A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism.
Salpietro V, Dixon CL, Guo H, Bello OD, Vandrovcova J, Efthymiou S, Maroofian R, Heimer G, Burglen L, Valence S, Torti E, Hacke M, Rankin J, Tariq H, Colin E, Procaccio V, Striano P, Mankad K, Lieb A, Chen S, Pisani L, Bettencourt C, M?nnikk? R, Manole A, Brusco A, Grosso E, Ferrero GB, Armstrong-Moron J, Gueden S, Bar-Yosef O, Tzadok M, Monaghan KG, Santiago-Sim T, Person RE, Cho MT, Willaert R, Yoo Y, Chae JH, Quan Y, Wu H, Wang T, Bernier RA, Xia K, Blesson A, Jain M, Motazacker MM, Jaeger B, Schneider AL, Boysen K, Muir AM, Myers CT, Gavrilova RH, Gunderson L, Schultz-Rogers L, Klee EW, Dyment D, Osmond M, Parellada M, Llorente C, Gonzalez-Pe?as J, Carracedo A, Van Haeringen A, Ruivenkamp C, Nava C, Heron D, Nardello R, Iacomino M, Minetti C, Skabar A, Fabretto A, SYNAPS Study Group, Raspall-Chaure M, Chez M, Tsai A, Fassi E, Shinawi M, Constantino JN, De Zorzi R, Fortuna S, Kok F, Keren B, Bonneau D, Choi M, Benzeev B, Zara F, Mefford HC, Scheffer IE, Clayton-Smith J, Macaya A, Rothman JE, Eichler EE, Kullmann DM, Houlden H
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019 07 12; 10(1):3094.
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders.
Simmons RL, Li H, Alten B, Santos MS, Jiang R, Paul B, Lalani SJ, Cortesi A, Parks K, Khandelwal N, Smith-Packard B, Phoong MA, Chez M, Fisher H, Scheuerle AE, Shinawi M, Hussain SA, Kavalali ET, Sherr EH, Voglmaier SM
Overcoming presynaptic effects of VAMP2 mutations with 4-aminopyridine treatment. Hum Mutat. 2020 11; 41(11):1999-2011.
Overcoming presynaptic effects of VAMP2 mutations with 4-aminopyridine treatment.
Wechsler RT, Wheless J, Zafar M, Huesmann GR, Lancman M, Segal E, Chez M, Aboumatar S, Patten A, Salah A, Malhotra M
PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy. Epilepsia Open. 2022 06; 7(2):293-305.
PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy.
Wheless J, Wechsler RT, Penovich P, Segal E, Chez M, Coppola A, Datta A, D'Souza W, Najm I, Cappucci S, Sainz-Fuertes R, Villanueva V
Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study. Epilepsy Behav. 2023 Oct; 147:109369.
Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study.
Yamamoto T, Chez M, Campos D, Lattanzi S, Matricardi S, Est?vez-Mar?a JC, D'Souza W, Trinka E, Cappucci S, Villanueva V
Effectiveness and safety of perampanel by concomitant antiseizure medications: Insights from the real-world PERMIT Extension study. Epilepsy Behav. 2025 Oct; 171:110651.
Effectiveness and safety of perampanel by concomitant antiseizure medications: Insights from the real-world PERMIT Extension study.
Acute septic arthritis due to Acremonium. J Rheumatol. 1988 Apr; 15(4):714-5.
Acute septic arthritis due to Acremonium.
Chez MG, Bourgeois BF, Pippenger CE, Knowles WD
Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice. Clin Neuropharmacol. 1994 Feb; 17(1):32-7.
Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice.
Pranzatelli MR, Kao PC, Tate ED, Chaves E, Chez M, Dobyns WB, Kang H, Rothner DA
Antibodies to ACTH in opsoclonus-myoclonus. Neuropediatrics. 1993 Jun; 24(3):131-3.
Antibodies to ACTH in opsoclonus-myoclonus.
Lewine JD, Andrews R, Chez M, Patil AA, Devinsky O, Smith M, Kanner A, Davis JT, Funke M, Jones G, Chong B, Provencal S, Weisend M, Lee RR, Orrison WW
Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics. 1999 Sep; 104(3 Pt 1):405-18.
Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders.
Sandler RH, Bolte ER, Chez MG, Schrift MJ
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Relief of psychiatric symptoms in a patient with Crohn's disease after metronidazole therapy. Clin Infect Dis. 2000 Jan; 30(1):213-4.
Relief of psychiatric symptoms in a patient with Crohn's disease after metronidazole therapy.
Chez MG, Buchanan CP, Bagan BT, Hammer MS, McCarthy KS, Ovrutskaya I, Nowinski CV, Cohen ZS
Secretin and autism: a two-part clinical investigation. J Autism Dev Disord. 2000 Apr; 30(2):87-94.
Secretin and autism: a two-part clinical investigation.
Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, Komen J
Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov; 17(11):833-7.
Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders.
Aman MG, Novotny S, Samango-Sprouse C, Lecavalier L, Leonard E, Gadow KD, King BH, Pearson DA, Gernsbacher MA, Chez M
Outcome measures for clinical drug trials in autism. CNS Spectr. 2004 Jan; 9(1):36-47.
Outcome measures for clinical drug trials in autism.
Immunizations, immunology, and autism. Semin Pediatr Neurol. 2004 Sep; 11(3):214-7.
Neurologic treatment strategies in autism: an overview of medical intervention strategies. Semin Pediatr Neurol. 2004 Sep; 11(3):229-35.
Neurologic treatment strategies in autism: an overview of medical intervention strategies.
Chez MG, Chang M, Krasne V, Coughlan C, Kominsky M, Schwartz A
Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behav. 2006 Feb; 8(1):267-71.
Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005.
Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment. Paediatr Drugs. 2009; 11(6):397-406.
Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics. 2010 Jul; 7(3):293-301.
Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.
Safety and observations in a pilot study of lenalidomide for treatment in autism. Autism Res Treat. 2012; 2012:291601.
Safety and observations in a pilot study of lenalidomide for treatment in autism.
Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M
Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem Cells Transl Med. 2018 04; 7(4):333-341.
Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism.
Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, Miller I, Nichol K, Park Y, Segal E, Seltzer L, Szaflarski JP, Thiele EA, Weinstock A, CBD EAP study group
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019 08; 154:13-20.
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Flamini RJ, Comi AM, Bebin EM, Chez MG, Clark G, Devinsky O, Hussain SA, Lyons PD, Patel AD, Rosengard JL, Sahebkar F, Segal E, Seltzer L, Szaflarski JP, Weinstock A
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program. Epilepsia. 2023 08; 64(8):e156-e163.
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program.
Sankar R, Chez M, Pina-Garza JE, Dixon-Salazar T, Flamini JR, Hyslop A, McGoldrick P, Millichap JJ, Resnick T, Rho JM, Wolf S
Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion. Seizure. 2023 Aug; 110:42-57.
Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion.
Pina-Garza JE, Chez M, Cloyd J, Hirsch LJ, K?lvi?inen R, Klein P, Lagae L, Sankar R, Specchio N, Strzelczyk A, Toledo M, Trinka E
Epileptic disorders : international epilepsy journal with videotape
Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: Consensus recommendations of an expert working group. Epileptic Disord. 2024 Aug; 26(4):484-497.
Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: Consensus recommendations of an expert working group.
Chez M, Klein P, Becker D, Peters JM, Carrazana E, Rabinowicz AL
Exploring proposed recommendations for immediate-use seizure medication: Treating both cluster and prolonged seizures with diazepam nasal spray. Epilepsia Open. 2025 Aug; 10(4):999-1008.
Exploring proposed recommendations for immediate-use seizure medication: Treating both cluster and prolonged seizures with diazepam nasal spray.